MannKind Corporation - Common Stock (MNKD)

4.0350
-0.0350 (-0.86%)
NASDAQ · Last Trade: Nov 19th, 1:34 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Tractionmarketbeat.com
MannKind (NASDAQ:MNKD) expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza, CEO Michael Castagna said at the Jefferies 2026 Global Healthcare Conference. Castagna outlined thr
Via MarketBeat · November 18, 2026
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectationsmarketbeat.com
MannKind (NASDAQ:MNKD) is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma Conference in London. Castagna said MannKind expects to be profitable next year after a period of inve
Via MarketBeat · November 18, 2026
MannKind (MNKD) Q3 2026 Earnings Call Transcriptfool.com
Furoscix ReadyFlow conversion reached 75% within six weeks of launch.
Via The Motley Fool · November 6, 2026
MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenuechartmill.com
Via Chartmill · August 5, 2026
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progresschartmill.com
Via Chartmill · May 6, 2026
MannKind Corp (NASDAQ:MNKD) Reports Q4 2025 Revenue Beat and Strategic Outlook for 2026chartmill.com
Via Chartmill · February 26, 2026
MannKind Q3 Earnings Call Highlightsmarketbeat.com
MannKind (NASDAQ:MNKD) expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company’s FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction. Revenue rose 24% to $101.9 million from $82.1 million a year earlier, Chief
Via MarketBeat · November 6, 2026
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growthmarketbeat.com
MannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF, following early safety and tolerability results that did not show the gastrointestinal issues often assoc
Via MarketBeat · October 20, 2026
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentummarketbeat.com
MannKind (NASDAQ:MNKD) CFO Chris Prentiss outlined the company’s commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase
Via MarketBeat · September 17, 2026
MannKind Q2 Earnings Call Highlightsmarketbeat.com
MannKind (NASDAQ:MNKD) reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs. The company recorded a GAAP net loss of $19
Via MarketBeat · August 5, 2026
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underwaymarketbeat.com
MannKind (NASDAQ:MNKD) reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability. The company’s INFLO-1 trial
Via MarketBeat · July 29, 2026
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPEmarketbeat.com
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload. Chief Executive Officer Michael Castagna said the approval
Via MarketBeat · July 24, 2026
What This MannKind Filing Reveals About Three Years of Underperformancefool.com
Performance-based RSUs vested at 83% of target, reflecting MannKind's stock performance against industry benchmarks. Singh retains ~479,000 shares valued at $1.96 million.
Via The Motley Fool · July 20, 2026
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Riskfool.com
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.
Via The Motley Fool · July 20, 2026
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Millionfool.com
This disposition was tied to vesting of performance-based RSUs at 83% of the target.
Via The Motley Fool · July 20, 2026
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Riskfool.com
Tross disposed of 65,808 shares to cover tax withholding from a vested performance award, retaining over 1 million shares in the company.
Via The Motley Fool · July 20, 2026
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares?fool.com
Castagna retains 2.4 million shares after the non-discretionary sale tied to RSU vesting, maintaining substantial alignment with the biopharmaceutical company.
Via The Motley Fool · July 19, 2026
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Marketmarketbeat.com
MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin’s label into children and adolescents. Chief Executive Officer Michael Castagna called the decision “a truly historic
Via MarketBeat · May 30, 2026
MannKind (MNKD) Q1 2026 Earnings Transcriptfool.com
MannKind (MNKD) Q1 2026 Earnings Transcript
Via The Motley Fool · May 6, 2026
Keep an eye on the top gainers and losers in Wednesday's session.chartmill.com
Via Chartmill · May 6, 2026
Wednesday's session: gap up and gap down stockschartmill.com
Via Chartmill · May 6, 2026
What's Going On With MannKind Stock Friday?benzinga.com
MannKind Corp. (NASDAQ: MNKD) reported strong Q4 and FY 2025 results, with earnings and sales beating expectations.
Via Benzinga · February 27, 2026
Why MannKind Stock Tumbled on Thursdayfool.com
Mr. Market was hoping for a better fourth quarter than the company delivered.
Via The Motley Fool · February 26, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · February 25, 2026
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’stocktwits.com
United Therapeutics unveiled a new product called Tresmi, which is “a proprietary drug device formulation of treprostinil into a soft mist inhaler.”
Via Stocktwits · February 25, 2026